Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Shares Purchased by EcoR1 Capital LLC

EcoR1 Capital LLC increased its stake in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 466.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,115,000 shares of the company’s stock after purchasing an additional 2,565,000 shares during the period. Centessa Pharmaceuticals makes up 3.5% of EcoR1 Capital LLC’s holdings, making the stock its 5th largest position. EcoR1 Capital LLC’s holdings in Centessa Pharmaceuticals were worth $77,906,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Foresite Capital Management VI LLC boosted its stake in Centessa Pharmaceuticals by 4.8% in the 3rd quarter. Foresite Capital Management VI LLC now owns 1,314,019 shares of the company’s stock worth $31,865,000 after purchasing an additional 60,640 shares during the period. Eagle Health Investments LP acquired a new position in Centessa Pharmaceuticals in the 3rd quarter worth $2,500,000. SG Americas Securities LLC boosted its stake in Centessa Pharmaceuticals by 1,017.7% in the 4th quarter. SG Americas Securities LLC now owns 263,625 shares of the company’s stock worth $6,593,000 after purchasing an additional 240,039 shares during the period. Royce & Associates LP acquired a new position in Centessa Pharmaceuticals in the 3rd quarter worth $5,999,000. Finally, Avoro Capital Advisors LLC boosted its stake in Centessa Pharmaceuticals by 116.2% in the 3rd quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock worth $262,096,000 after purchasing an additional 5,808,080 shares during the period. 82.01% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Monday, April 20th. Wells Fargo & Company lowered shares of Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and upped their target price for the stock from $35.00 to $42.00 in a research note on Monday, April 20th. Stephens lowered shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Truist Financial cut Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 price objective for the company. in a report on Monday, April 13th. Finally, B. Riley Financial downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Four research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $41.33.

Centessa Pharmaceuticals Stock Performance

NASDAQ CNTA opened at $39.87 on Thursday. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.23. The company has a market capitalization of $6.17 billion, a P/E ratio of -22.27 and a beta of 1.11. Centessa Pharmaceuticals PLC Sponsored ADR has a 12-month low of $12.30 and a 12-month high of $40.26. The firm has a 50-day moving average price of $39.65 and a two-hundred day moving average price of $31.11.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). Analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Karen M. Anderson sold 41,076 shares of the stock in a transaction that occurred on Thursday, March 26th. The shares were sold at an average price of $30.12, for a total value of $1,237,209.12. Following the completion of the transaction, the insider owned 62,085 shares of the company’s stock, valued at $1,870,000.20. This represents a 39.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.09% of the stock is currently owned by insiders.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.